摘要
目的探讨奥沙利铂联合卡培他滨(XELOX)方案一线治疗进展期胃癌的疗效和不良反应。方法回顾性分析71例经病理组织学检查证实的胃癌患者,给予XELOX方案化疗,具体为:奥沙利铂130mg/m2静滴,第1天;卡培他滨1000mg/m2口服,2次/日,第1～14天,21天为1周期。记录治疗的有效率(RR)、疾病进展时间(TTP)、总生存时间(OS)和不良反应。结果 71例患者共完成320个周期化疗,RR为43.7%(95%CI:36.3%～62.9%),包括CR 5例(7.0%),PR 26例(36.6%),中位TTP为7.5个月(95%CI:6.4～8.5个月),中位OS为11个月(95%CI:8.2～13.8个月)。主要不良反应以1～2级为主,3级不良反应包括恶心呕吐4例、腹泻5例、外周感觉神经症状5例、手足综合征7例和中性粒细胞缺乏6例,无化疗相关性死亡。结论 XELOX方案一线治疗进展期胃癌疗效较好,毒副反应可以耐受,使用方便,值得临床进一步研究。
Objective To explore oxaliplatin in combination with capecitabine（XELOX regimen） as first-line chemotherapy in advanced gastric cancer（AGC）.Methods Seventy-one patients with histologically confirmed gastric cancer were retrospectively analyzed.All of the patients were prescribed oxaliplatin 130 mg/m2 intravenously on day 1 and capecitabine 1000 mg/m2 orally twice a day,on days 1-14.Twenty-one days was a cycle.The primary endpoint was response rate（RR）,and the secondary endpoint was time to progression（TTP）,overall survival（OS）and adverse events（AEs）.Results In total,320 cycles of XELOX were delivered.The tumor response rate was 43.7%（95% CI： 36.3%-62.9%）,with a complete response in 5（7.0%）cases and a partial response in 26（36.6%）cases.Median time to tumor progression was 7.5 months（95% CI：6.4-8.5）,and median survival time was 11 months（95% CI：8.2-13.8）.Most adverse events were mild to moderate,notable grade 3 events from the entire cohort included nausea/vomiting（4 cases）,diarrhea（5 cases）,peripheral sensory neuropathy（5 cases）,hand-foot syndrome（7 cases） and neutropenia（6 cases）.No chemotherapy related death occurred.Conclusion XELOX regimen is an effective regimen against AGC in the first-line treatment with favorable toxicity.Convenience with oral administration of every 3-week schedule makes XELOX regimen as a compelling therapeutic option in the first-line treatment of AGC,and merits further study.
出处
《临床肿瘤学杂志》
CAS
2011年第9期809-813,共5页
Chinese Clinical Oncology
关键词
胃癌
化学治疗
奥沙利铂
卡培他滨
Gastric cancer
Chemotherapy
Oxaliplatin
Capecitabine
